Switch theme
Sign up to access all valuation multiples
Massmedica SA is operating in the areas of reconstructive, regenerative, anti-aging and aesthetic medicine. It deals in the distribution of implants and other medical materials used in the treatment of diseases of the musculoskeletal system and in regenerative medicine.
2011
n/a
Last FY Revenue $8.6M
Last FY EBITDA $0.5M
$4.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Massmedica achieved revenue of $8.6M and an EBITDA of $0.5M.
Massmedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Massmedica valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $8.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $3.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 38% | XXX | XXX | XXX |
| EBITDA | XXX | $0.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 6% | XXX | XXX | XXX |
| EBIT | XXX | $0.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 4% | XXX | XXX | XXX |
| Net Profit | XXX | $0.2M | XXX | XXX | XXX |
| Net Margin | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | $1.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Massmedica's stock price is PLN 4 (or $1).
Massmedica has current market cap of PLN 10.2M (or $2.7M), and EV of PLN 15.4M (or $4.1M).
See Massmedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.1M | $2.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Massmedica has market cap of $2.7M and EV of $4.1M.
Massmedica's trades at 0.5x EV/Revenue multiple, and 8.5x EV/EBITDA.
Equity research analysts estimate Massmedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Massmedica's P/E ratio is not available.
See valuation multiples for Massmedica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.7M | XXX | $2.7M | XXX | XXX | XXX |
| EV (current) | $4.1M | XXX | $4.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 11.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 16.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -120.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMassmedica's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Massmedica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Massmedica's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Massmedica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Massmedica acquired XXX companies to date.
Last acquisition by Massmedica was XXXXXXXX, XXXXX XXXXX XXXXXX . Massmedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Massmedica founded? | Massmedica was founded in 2011. |
| Where is Massmedica headquartered? | Massmedica is headquartered in Poland. |
| Is Massmedica publicy listed? | Yes, Massmedica is a public company listed on WAR. |
| What is the stock symbol of Massmedica? | Massmedica trades under MSM ticker. |
| When did Massmedica go public? | Massmedica went public in 2019. |
| Who are competitors of Massmedica? | Similar companies to Massmedica include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Massmedica? | Massmedica's current market cap is $2.7M |
| Is Massmedica profitable? | Yes, Massmedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
